Wall Street Analysts Have Little Faith That Feds Can Slow Health Care M&A

During a recent panel discussion featuring equities analysts who cover the health care sector, analysts expressed skepticism that the rapid rate of mergers and acquisitions occurring in the industry will slow down in the near future — and they suggested that may not be such a bad thing.

“Can I just say no?” George Hill, a managing director at Deutsche Bank, said when asked whether tougher antitrust enforcement is having an impact on health care consolidation. Hill was one of four equities analysts who discussed market trends shaping the health care system during the USC-Brookings Schaeffer Initiative for Health Policy’s 27th “Wall Street Comes to Washington” roundtable.

0 Comments
© 2024 MMIT
Leslie Small

Leslie Small

Leslie has been working in journalism since 2009 and reporting on the health care industry since 2014. She has covered the many ups and downs of the Affordable Care Act exchanges, the failed health insurer mega-mergers, and hundreds of other storylines spanning subjects such as Medicaid managed care, Medicare Advantage, employer-sponsored insurance, and prescription drug coverage. As the managing editor of Health Plan Weekly and Radar on Drug Benefits, she writes and edits for both publications while overseeing a small team of reporters who also focus on the managed care sector. Before joining AIS Health, she was a senior editor for the e-newsletter Fierce Health Payer, and she started her career as a copy editor at multiple local newspapers. She graduated with a dual degree in journalism and political science from Penn State University.

Related Posts

department-of-justice-building
September 30

Loss in UnitedHealth/Change Trial May Not Lower DOJ’s Deal-Blocking Appetite

READ MORE
cvs-health-building
February 10

Oak Street Deal Could Be Boon for CVS Health — If Firm Can Pull It Off

READ MORE
louisiana
January 27

Elevance’s Louisiana Purchase Could Portend More Blue Cross Blue Shield Consolidation

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today